Show simple item record

dc.contributor.authorReid, Gen
dc.contributor.authorLorigan, Paul Cen
dc.contributor.authorHeimann, Hen
dc.contributor.authorHovan, Men
dc.date.accessioned2018-06-27T20:08:18Z
dc.date.available2018-06-27T20:08:18Z
dc.date.issued2018-04-19
dc.identifier.citationManagement of chronic hypotony following bilateral uveitis in a patient treated with pembrolizumab for cutaneous metastatic melanoma. 2018, 1-4 Ocul Immunol Inflammen
dc.identifier.issn1744-5078
dc.identifier.pmid29672247
dc.identifier.doi10.1080/09273948.2018.1459733
dc.identifier.urihttp://hdl.handle.net/10541/621059
dc.description.abstractTo describe the presentation and management of severe ocular adverse events following treatment with pembrolizumab for cutaneous metastatic melanoma.
dc.language.isoenen
dc.rightsArchived with thanks to Ocular immunology and inflammationen
dc.titleManagement of chronic hypotony following bilateral uveitis in a patient treated with pembrolizumab for cutaneous metastatic melanoma.en
dc.typeArticleen
dc.contributor.departmentDepartment of Ophthalmology , Royal Victoria Hospital , Belfast , Northern Irelanden
dc.identifier.journalOcular Immunology and Inflammationen
html.description.abstractTo describe the presentation and management of severe ocular adverse events following treatment with pembrolizumab for cutaneous metastatic melanoma.


This item appears in the following Collection(s)

Show simple item record